Ken Galbraith

AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases.

Novadaq Technologies, Inc. was engaged in the development, manufacture, and market of real-time fluorescence imaging products. The company was founded by Rick Mangat on April 14, 2000 and was headquartered in Mississauga, Canada.

Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.

Syncona Ltd. is a closed-end investment fund. It engages in delivering returns from investments in long and alternative investment funds across multiple asset classes and targets. The company was founded on August 14, 2012, and is headquartered in St. Peter Port, the United Kingdom.

Genesys Capital Partners Inc (Genesys Capital) is an independent venture capital firm founded in 2000 by Damian Lamb, Plumley and Kelly Holman. The firm is headquartered in Toronto.

Ventures West Management, Inc. is venture capital firm headquartered in Vancouver, British Columbia with additional offices in Toronto, Montréal and Kanata, Ontario

Celator Pharmaceuticals Corp. is an oncology-based biopharmaceutical company. It focuses on a proprietary technology platform which evaluates combinations of anti-cancer drugs for enhanced anti-cancer activity. The company was founded by Lawrence David Mayer and is headquartered in Vancouver, Canada.

Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA.

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada.

NeurAxon, Inc. is engaged in the research and development of growing and unmet needs for chronic pain management. It is focused on developing pain therapeutics targeting neuronal Nitric Oxide Synthase (nNOS) inhibitors. The companyw as founded in 2004 and is headquartered in Mississauga, ON.

Presidio Pharmaceuticals, Inc. discovers and develops small-molecule antiviral therapeutics. Its products in pipeline include NS5A, PPI-668 and PPI-383 for treating hepatitis C virus infections. The company was founded by Omar K. Haffar, Antoun Nabhan and David V. Jobes in March 2006 and is headquartered in San Francisco, CA.

Part of Herschend Family Entertainment Corp., Vancouver Aquarium operates an aquarium. The private company is based in Vancouver, Canada. Vancouver Aquarium was acquired by Herschend Family Entertainment Corp. from Ocean Wise Conservation Association on April 15, 2021. The Canadian company was founded in 1951.

AudienceView Ticketing Corp. engages in the provision and development of software and media solutions for ticket sales. It offers services through its platform, which under the brands of OvationTix, Vendini, TheaterMania, WhatsOnStage, LaughStub, ElectroStub, and TuneStub. The company was founded by Kevin Kimsa and Paul J. Atkinson in 2002 and is headquartered in Toronto, Canada.

Augurex Life Sciences Corp. develops biomarkers that transform patient clinical management. Its biomarkers substances in the body that inform patient conditions and assist with diagnosis, treatment and disease monitoring. The company’s first biomarker Extracellular 14-3-3eta protein, serves as a drug target for the potential treatment of rheumatoid arthritis (RA). Augurex Life Sciences was founded by Norma K. Biln and Anthony Marotta in October 2007 and is headquartered in Vancouver, Canada.

Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom.

Five Corners Capital Inc (Five Corners Capital) is a venture capital firm founded in 2013 by Kenneth Galbraith and Gary Bridger. The firm is headquartered in British Columbia, Canada.

Part of Liminal R & D BioSciences, Inc., Liminal BioSciences Ltd. is a British biopharmaceutical company founded in 2015. The private company is based in Comberton, UK. The company is focused on the discovery and development of novel, small molecule drug candidates.

Prometic Plasma Resources (USA), Inc. is based in Albany, NY. Part of KEDRION HOLDING S.P.A., Prometic Plasma Resources (USA), Inc. is a company that manufactures and distributes biopharmaceutical products. The CEO of the company is Kenneth Harry Galbraith.

Kalium Health Ltd. engages in the provision of clinical, technological, and healthcare services. It provides personalized electrolyte monitoring. The company was founded by Fiona Karet and Tom Collings and is headquartered in Cambridge, the United Kingdom.

Fairhaven Pharmaceuticals, Inc. engages in the research and development of small molecule antagonists that target chemoattractant and activator of eosinophils, which play a key role in type 2 inflammation-driven diseases. The company was founded on May 4, 2018 and is headquartered in Laval, Canada.